treatment-resistant depression
Articles tagged with “treatment-resistant depression”
Wisconsin Man's Depression Story: What Oral Ketamine Offers
A Wisconsin man's ketamine treatment success raises awareness of oral tablet options for depression. What patients should know before starting.
Study: Ketamine Relieves Treatment-Resistant Depression
New research highlights ketamine's potential against resistant depression and suicidal thoughts. Here's what tablet users need to know about access and dosing.
Boston Clinics Spotlight Ketamine's Mental Health Role
Boston health clinics are expanding ketamine therapy for depression and PTSD — here's what it means for patients exploring oral ketamine tablets.
One Patient's Year With Ketamine and Experimental Care
A Guardian journalist tried ketamine and other cutting-edge depression treatments for a year. What oral ketamine patients can learn from her experience.
How Symptom Tracking Reshapes Oral Ketamine Dosing for TRD
Regular symptom tracking and faster dose adjustments drive TRD remission sooner. Here's what that means for oral ketamine tablet users.
NMDA Antagonist Side Effects: What Tablet Users Need to Know
New clinical data on NMDA antagonist side effects and dropout rates has real implications for oral ketamine tablet users. Here's what the research means for you.
Why Patients Quit Ketamine Early—And How Tablets Factor In
New clinical data on NMDA antagonist dropout rates reveals how side effect management and route of administration affect treatment-resistant depression outcomes.
TRD Guidelines Spotlight Ketamine's Growing Role
Psychiatric Times highlights optimizing TRD treatments in 2026. Here's what it means for patients using oral ketamine tablets for depression.
Oral Ketamine Side Effects: What New TRD Data Tells Us
New clinical guidance on NMDA antagonist side effects and discontinuation rates offers key lessons for oral ketamine tablet users managing treatment-resistant depression.
NMDA Antagonist Side Effects: What Tablet Users Should Know
New research in Psychiatric Times breaks down side effect profiles and discontinuation rates for NMDA antagonists — here's what it means for oral ketamine tablet users.
Ketamine Side Effects & Dropout Rates: What Data Says
New analysis in Psychiatric Times urges data-driven ketamine dosing. Here's what the side-effect and dropout data means for oral tablet users.
Glutamate Pathway Treatments Reshape TRD Care in 2026
New research highlights how glutamate-targeting drugs like esketamine and ketamine are reshaping treatment-resistant depression care. Here's what it means for oral ketamine users.
Faster TRD Remission: What Dose Optimization Means
New clinical guidance on TRD care emphasizes rapid dose adjustment and symptom tracking — here's what it means for oral ketamine tablet patients.
Glutamate Pathway Treatments Reshaping TRD Care
New research highlights glutamate-based therapies like esketamine and ketamine tablets for treatment-resistant depression. Here's what it means for oral ketamine users.
Insurance Gaps Push Patients Toward Oral Ketamine
Ketamine insurance claim denied? How oral ketamine tablets offer an affordable depression treatment path, plus appeals tips and cash-pay tablet pricing.
How Doctors Choose TRD Treatments in 2026
How clinicians choose ketamine treatments for treatment-resistant depression in 2026, including when oral tablets are picked over IV, IM, or nasal spray.
Esketamine for Treatment-Resistant Depression in 2026
Esketamine (Spravato) for treatment-resistant depression compared to ketamine tablets: efficacy, monitoring, cost, and which oral or nasal option fits.
Glutamate Pathway Drugs Are Reshaping TRD Care
How ketamine acts on the glutamate pathway in treatment-resistant depression and why oral tablet therapy targets the same NMDA receptors as IV ketamine.
Why Remission—Not Just Relief—Changes Ketamine Care
New clinical guidance pushes beyond symptom reduction toward full remission in TRD. Here's what that means for oral ketamine tablet users.
Ketamine's Role in Treatment-Resistant Depression Care
Psychiatric Times highlights ketamine among top TRD approaches. Here's what oral ketamine tablet users need to know about access and dosing.
BPL-003 Shows Sustained TRD Relief in Phase 2a Trial
Beckley Psytech's BPL-003 phase 2a part 2 data shows lasting symptom reduction in treatment-resistant depression — what it means for the TRD landscape.
Contact Ketamine Tablet
Send corrections, provider questions, or advertising inquiries.